Published : 15 Jul 2021

---

A Pennsylvania Biopharma Therapeutics company (Subsidiary of a Biotech company from China) has appointed Aagami for supporting their out-licensing/co-development initiatives globally. 

The company is developing several oncology assets such as Docetaxel, Cabazitaxel and Bendamustine, with low cost and accelerated route to market approval.

Ingenio’s lead candidate IN1001 is a reformulated docetaxel injection using SBECD to replace two unfavorable excipients (ethanol and polysorbate 80) present in the original formulation of Taxotere (Sanofi) that necessitates hormone premedication(dexamethasone) to minimize potentially serious adverse events (fatal allergic reactions, fluid retention, addiction etc.).

 

Besides IN1001, other compelling assets such as IN1006 (Cabazitaxel) and IN1043 (Bendamustine Hydrochloride) are also available for partnering. 

 

Non-confidential presentations are available for review. Please contact us to know more.